WO2001061360A3 - Identification of modulators of gpr31 activity - Google Patents

Identification of modulators of gpr31 activity Download PDF

Info

Publication number
WO2001061360A3
WO2001061360A3 PCT/GB2001/000693 GB0100693W WO0161360A3 WO 2001061360 A3 WO2001061360 A3 WO 2001061360A3 GB 0100693 W GB0100693 W GB 0100693W WO 0161360 A3 WO0161360 A3 WO 0161360A3
Authority
WO
WIPO (PCT)
Prior art keywords
gpr
activity
identification
protein
gpr31
Prior art date
Application number
PCT/GB2001/000693
Other languages
French (fr)
Other versions
WO2001061360A2 (en
Inventor
Alan Wise
Original Assignee
Glaxo Group Ltd
Alan Wise
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd, Alan Wise filed Critical Glaxo Group Ltd
Priority to AU33895/01A priority Critical patent/AU3389501A/en
Publication of WO2001061360A2 publication Critical patent/WO2001061360A2/en
Publication of WO2001061360A3 publication Critical patent/WO2001061360A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Abstract

The present invention provides a method for identification of an agent that modulates activity of G-protein coupled receptor 31 (GPR 31). The method comprises: (i) contacting a test agent with GPR 31 or a variant thereof which is capable of coupling to a G-protein; and (ii) monitoring for GPR 31 activity in the presence of a G-protein; thereby determining whether the test agent modulates GPR 31 activity. The invention also provides activators of GPR 31, inhibitors of lipolysis and GPR 31 polynucleotides which can be used in the treatment of dyslipidaemia, coronary heart disease, atheroscloresis, thrombosis or obesity, angina, chronic renal failure, peripheral vascular disease, stroke, type I diabetes or metabolic syndrome (syndrome X).
PCT/GB2001/000693 2000-02-18 2001-02-19 Identification of modulators of gpr31 activity WO2001061360A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU33895/01A AU3389501A (en) 2000-02-18 2001-02-19 Assay

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0003898.4 2000-02-18
GBGB0003898.4A GB0003898D0 (en) 2000-02-18 2000-02-18 Assay

Publications (2)

Publication Number Publication Date
WO2001061360A2 WO2001061360A2 (en) 2001-08-23
WO2001061360A3 true WO2001061360A3 (en) 2002-03-28

Family

ID=9885980

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/000693 WO2001061360A2 (en) 2000-02-18 2001-02-19 Identification of modulators of gpr31 activity

Country Status (3)

Country Link
AU (1) AU3389501A (en)
GB (1) GB0003898D0 (en)
WO (1) WO2001061360A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040254224A1 (en) * 2001-04-11 2004-12-16 Foord Steven Michael Medicaments
WO2005059561A2 (en) * 2003-12-12 2005-06-30 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 31 (gpr31)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000022129A1 (en) * 1998-10-13 2000-04-20 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human g protein-coupled receptors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000022129A1 (en) * 1998-10-13 2000-04-20 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human g protein-coupled receptors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL 21 August 2000 (2000-08-21), BEHAN D P ET AL: "Non-endogenous constitutively activated human G protein-coupled receptors, useful for identifying agonists for use as pharmaceutical agents", XP002174049 *
SOEDER KURT J ET AL: "The beta3-adrenergic receptor activates mitogen-activated protein kinase in adipocytes through a Gi-dependent mechanism.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 17, 23 April 1999 (1999-04-23), pages 12017 - 12022, XP002174047, ISSN: 0021-9258 *
WALSTON J ET AL: "The beta3-adrenergic receptor in the obesity and diabetes prone rhesus monkey is very similar to human and contains arginine at codon 64", GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES,GB,ELSEVIER SCIENCE PUBLISHERS, BARKING, vol. 188, no. 2, 1 April 1997 (1997-04-01), pages 207 - 213, XP004059301, ISSN: 0378-1119 *
ZINGONI ALESSANDRA ET AL: "Isolation and chromosomal localization of GPR31, a human gene encoding a putative G protein-coupled receptor.", GENOMICS, vol. 42, no. 3, 1997, pages 519 - 523, XP002174048, ISSN: 0888-7543 *

Also Published As

Publication number Publication date
WO2001061360A2 (en) 2001-08-23
GB0003898D0 (en) 2000-04-05
AU3389501A (en) 2001-08-27

Similar Documents

Publication Publication Date Title
Kim et al. High-sensitivity detection for model organophosphorus and carbamate pesticide with quartz crystal microbalance-precipitation sensor
BR0009865A (en) Measurement and use of molecular interactions
MX9706785A (en) Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an antacid agent or alginate.
WO2001061359A3 (en) Identification of modulators of gpr41 or gpr42 activity
HK1055235A1 (en) Method and apparatus for estimating pulmonary artery pressure
MA31749B1 (en) Soluble soybean tonic
WO2008041953A3 (en) Dengue diagnosis and treatment
NO20021197L (en) Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
ATE331960T1 (en) DIAGNOSIS OF MYOCARDIAL INFARCTION AND ACUTE CORONARY SYNDROME BY COMBINATION OF MARKERS
ATE514084T1 (en) SENSOR FOR DETECTING CARBOHYDRATE
IS2793B (en) Use of 3-hydroxy-3-methylglutaryl auxiliary enzyme A antacid inhibitors for the manufacture of a medicament for the treatment of diabetes mellitus
WO2001061360A3 (en) Identification of modulators of gpr31 activity
Westhoff et al. The cardiovascular effects of upper-limb aerobic exercise in hypertensive patients
Grassi et al. Changes in plasma catecholamines in response to reflex modulation of sympathetic vasoconstrictor tone by cardiopulmonary receptors.
DE502006003494D1 (en) DETERMINATION OF DIAMINE OXIDASE
DE69841710D1 (en) Building board for the production of buildings
DE60238699D1 (en) MULTIPLE ANALYTASSAY DEVICE WITH MULTI-SPOT DETECTION ZONE
WO2001044497A3 (en) Protein kinase regulation
Meyer et al. Delayed VO2 kinetics during ramp exercise: a criterion for cardiopulmonary exercise capacity in chronic heart failure.
ATE503021T1 (en) METHOD FOR DETECTING ENDOGLYCOSIDASE ACTIVITY
WO2003087761A3 (en) Molecular profiling of disease and therapeutic response using phospho-specific antibodies
PT1307427E (en) PROCESS FOR THE CYANACATION OF ALDEIDOS
ATE15387T1 (en) METHODS FOR DETERMINING ENZYME INHIBITOR COMPLEXES.
ATE279924T1 (en) 3-CYCLOPROPYLMETHOXY-4-DIFLUOROMETHOXY-N-(3,5-DICHLORO-PYRID-4-YL)-BENZAMIDE FOR THE TREATMENT OF MULTIPLE SCLERosis
WO2002034918A3 (en) E. coli 0157:h7 c1 esterase inhibitor-binding protein stce and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP